Home › Non-Small Cell Lung Cancer › New York
Non-Small Cell Lung Cancer clinical trials in New York
169 studies for Non-Small Cell Lung Cancer are looking for participants at sites in New York.
Cities in New York
- New York City120 studies
- Queens49 studies
- Greenburgh28 studies
- The Bronx25 studies
- Staten Island19 studies
- New Rochelle18 studies
- Buffalo18 studies
- Syracuse15 studies
- Rochester13 studies
- Albany9 studies
- Brooklyn5 studies
- Shirley5 studies
- West Albany4 studies
- Yonkers4 studies
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Northwell Health Imbert Cancer Center, Bay Shore
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- and 18 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Roswell Park Cancer Institute ( Site 0184), Buffalo
- Hematology-Oncology Associates of CNY ( Site 0164), East Syracuse
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216), New York
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06623422Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- New York Cancer & Blood Specialists - New Hyde Park, New Hyde Park
- New York Cancer & Blood Specialists - Cancer Center - Research Headquarters, New York
- New York Cancer & Blood Specialists - Patchogue Medical Oncology, Patchogue
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06472245A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- New York Proton Center, New York
- and 9 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Local Institution - 0080, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07680764A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- NYU Langone Hospital Long Island, Mineola
- NYU Langone Hospital Manhattan, New York
- Jacobi Medical Center - Albert Einstein College of Medicine, The Bronx
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07365319A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START New York Long Island LLC, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
- Exelixis Clinical Site #76, Syracuse
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- New York Oncology Hematology, P.C. ( Site 9000), Albany
- White Plains Hospital ( Site 3213), White Plains
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07513376A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Roswell Park Cancer Institute IDS, Buffalo
- Memorial Sloan Kettering Hospital, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Hematology Oncology Associates of CNY at Camillus, Camillus
- Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse
- Stony Brook University Medical Center, Stony Brook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07388524Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06625775A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- New York Oncology Hematology P.C ( Site 9000), Albany
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07554339A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- New York Oncology Hematology, P.C. ( Site 0119), Albany
- Wilmot Cancer Institute ( Site 0141), Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center-Weiler Hospital, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Memorial Sloan Kettering Cancer Center, New York
- Optum Medical Care, PC, Westbury
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361497A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0224, Laurelton
- Memorial Sloan Kettering Cancer Center, New York
- Optum Medical Care, PC, Westbury
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361510A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- NYU, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07659782Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- NYU Langone's Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Optum Medical Care, PC, Westbury
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- New York Cancer And Blood Specialists - Shirley /ID# 272547, Shirley
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, The Bronx
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06881784A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Montefiore Medical Center - Montefiore Medical Park, The Bronx
- White Plains Hospital, White Plains
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Cayuga Medical Center ( Site 0086), Ithaca
- University Hospital at Stony Brook ( Site 0054), Stony Brook
- White Plains Hospital ( Site 0091), White Plains
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- New York Oncology Hematology, Albany
- New York Oncology Hematology, Clifton Park
- Hematology Oncology Associates of Rockland, Nyack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, New York
- Research Site, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
- New York University Langone Medical Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07227025Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- NYU Langone Medical Center, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Hematology Oncology Associates of Rockland, Nyack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Hematology-Oncology Associates of CNY, East Syracuse
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center, New York
- and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667908Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Montefiore Medical Center- Montefiore Medical Park, The Bronx
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07227298A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Buffalo
- Research Site, East Syracuse
- Research Site, Fresh Meadows
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06868277Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Northport VA Medical Center, Northport
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598Pan-tumor MRD Study
- Guthrie Lourdes Memorial Hospital (GLMH), Binghamton
- New York Cancer & Blood Specialists, Shirley
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Veterans Affairs New York Harbor Healthcare System, New York
- University of Rochester Medical Center, Rochester
- Local Institution - 0511, Schenectady
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06561386Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Stony Brook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06357533Intratumoral N17350 in Advanced Solid Tumors
- Roswell Park Comprehensive Cancer Center, Buffalo
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07339176From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.